Zobrazeno 1 - 10
of 16
pro vyhledávání: '"Daniel S. Bejan"'
Development of a nanoparticle-based immunotherapy targeting PD-L1 and PLK1 for lung cancer treatment
Autor:
Moataz Reda, Worapol Ngamcherdtrakul, Molly A. Nelson, Natnaree Siriwon, Ruijie Wang, Husam Y. Zaidan, Daniel S. Bejan, Sherif Reda, Ngoc Ha Hoang, Noah A. Crumrine, Justin P. C. Rehwaldt, Akash Bindal, Gordon B. Mills, Joe W. Gray, Wassana Yantasee
Publikováno v:
Nature Communications, Vol 13, Iss 1, Pp 1-11 (2022)
Only a minority of patients with non-small cell lung cancer (NSCLC) respond to immune checkpoint inhibitors. Here the authors design a nanosystem for the co-delivery of a PLK1 inhibitor and PD-L1 antibody, showing anti-tumor immune responses in precl
Externí odkaz:
https://doaj.org/article/47471679aa7f42218b940fed0ac3e8d9
Autor:
Daniel S. Bejan, Sunil Sundalam, Haihong Jin, Rory K. Morgan, Ilsa T. Kirby, Ivan R. Siordia, Barr Tivon, Nir London, Michael S. Cohen
Publikováno v:
Chemical Science. 13:13898-13906
PARP16-the sole ER-resident PARP family member-is gaining attention as a potential therapeutic target for cancer treatment. Nevertheless, the precise function of the catalytic activity of PARP16 is poorly understood. This is primarily due to the lack
Autor:
Daniel J. Sanderson, Kelsie M. Rodriguez, Daniel S. Bejan, Ninni E. Olafsen, Inga D. Bohn, Ana Kojic, Sunil Sundalam, Ivan R. Siordia, Anna K. Duell, Nancy Deng, Carsten Schultz, Denis M. Grant, Jason Matthews, Michael S. Cohen
Publikováno v:
Cell Chemical Biology. 30:43-54.e8
The mono-ADP-ribosyltransferase PARP7 has emerged as a key negative regulator of cytosolic NA-sensors of the innate immune system. We apply a rational design strategy for converting a pan-PARP inhibitor into a potent selective PARP7 inhibitor (KMR-20
Publikováno v:
Journal of Chemical Crystallography. 50:387-399
In the solid state, some 3-substituted 4-hydroxycoumarins β-ketoester enols form infinite translational hydrogen-bonded β-chains with varying degrees of alignment between adjacent delocalized systems. Nine related structures have been studied. At t
Autor:
Worapol Ngamcherdtrakul, Daniel S. Bejan, William Cruz‐Muñoz, Moataz Reda, Husam Y. Zaidan, Natnaree Siriwon, Suphalak Marshall, Ruijie Wang, Molly A. Nelson, Justin P. C. Rehwaldt, Joe W. Gray, Kullervo Hynynen, Wassana Yantasee
Publikováno v:
Small
The first-line treatment of advanced and metastatic human epidermal growth factor receptor type 2 (HER2+) breast cancer requires two HER2-targeting antibodies (trastuzumab and pertuzumab) and a taxane (docetaxel or paclitaxel). The three-drug regimen
Autor:
Moriah R. Arnold, Marie-France Langelier, Jessica Gartrell, Ilsa T. Kirby, Daniel J. Sanderson, Daniel S. Bejan, Justina Šileikytė, Sunil K. Sundalam, Shanthi Nagarajan, Parthiban Marimuthu, Anna K. Duell, Anang A. Shelat, John M. Pascal, Michael S. Cohen
Publikováno v:
Cell Chemical Biology. 29:1694-1708.e10
Allosteric coupling between the DNA binding site to the NAD
Autor:
Ngoc Ha Hoang, Amanda W. Lund, Wassana Yantasee, Ruijie Wang, Shiuh Wen Luoh, Gordon B. Mills, Sancy A. Leachman, Worapol Ngamcherdtrakul, Joe W. Gray, Molly A. Nelson, Husam Y. Zaidan, Daniel S. Bejan, Moataz Reda, Ryan S. Lane
Publikováno v:
Adv Mater
The success of immunotherapy with immune checkpoint inhibitors (ICIs) in a subset of individuals has been very exciting. However, in many cancers, responses to current ICIs are modest and are seen only in a small subsets of patients. Herein, a widely
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::024b3bc7b166573fe36392d8a42ffd95
https://europepmc.org/articles/PMC8424660/
https://europepmc.org/articles/PMC8424660/
Autor:
Thanapon Sangvanich, Moataz Reda, Worapol Ngamcherdtrakul, Jingga Morry, Daniel S. Bejan, Glen E. Fryxell, Wassana Yantasee
Publikováno v:
Scientific Reports, Vol 9, Iss 1, Pp 1-9 (2019)
Scientific Reports
Scientific Reports
Gadolinium based contrast agents (GBCAs) have been linked to toxicity in patients, regardless of having impaired or normal renal function. Currently, no therapy is considered highly effective for removing gadolinium (Gd) from the body. We propose a n
Autor:
Natnaree Siriwon, Ngoc Ha Hoang, Molly A. Nelson, Gordon B. Mills, Ruijie Wang, Moataz Reda, Worapol Ngamcherdtrakul, Joe W. Gray, Wassana Yantasee, Daniel S. Bejan, Sherif Reda, Akash Bindal, Husam Y. Zaidan
Immune checkpoint inhibitors (ICIs) targeting PD-L1 and PD-1 have improved survival in a subset of patients with advanced non-small cell lung cancer (NSCLC). However, only a minority of NSCLC patients respond to ICIs, highlighting the need for superi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::98943fd021a16656657dbf11cabdf965
https://doi.org/10.21203/rs.3.rs-142908/v1
https://doi.org/10.21203/rs.3.rs-142908/v1
Autor:
Worapol Ngamcherdtrakul, Daniel S. Bejan, William Cruz‐Muñoz, Moataz Reda, Husam Y. Zaidan, Natnaree Siriwon, Suphalak Marshall, Ruijie Wang, Molly A. Nelson, Justin P. C. Rehwaldt, Joe W. Gray, Kullervo Hynynen, Wassana Yantasee
Publikováno v:
Small. 18:2270050